Scarica l'app Stockscreener
61.69
0.84%
-0.52
Pre-mercato:
61.36
-0.33
-0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Dexcom Inc Borsa (DXCM) Ultime notizie
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - TradingView
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
Morgan Stanley, Truist Cautious on DexCom (DXCM) Cites Weaker Gross Margins, Modest Q3 Beat - Insider Monkey
Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM) - Insider Monkey
Evercore Initiates Coverage on DexCom With In Line Rating, $68 Price Target - MarketScreener
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - Markets Financial Content
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing - GlobeNewswire
DexCom, Inc. Class Action: The Gross Law Firm Reminds - GlobeNewswire
Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the - GlobeNewswire
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc. - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Investors in DexCom, Inc. Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your RightsDXCM - Morningstar
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Notifies DexCom, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of DexCom, Inc. to Contact the Firm Today! - ACCESS Newswire
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - The Malaysian Reserve
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NewMediaWire
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DexCom Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
DCXM DEADLINE ALERT: DexCom, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit - GlobeNewswire
Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device - Yahoo Finance
Levi & Korsinsky Notifies Shareholders of DexCom, Inc. (DXCM) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing - Pharmacy Times
DXCM Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - Finviz
Dexcom to Release G7 15 Day CGM Next Month - Medical Product Outsourcing
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - GuruFocus
Dexcom G7 15 day continuous glucose monitoring system to launch on Dec. 1 in the United States - MarketScreener
Dexcom G7 15 Day Continuous Glucose Monitoring System To Launch On Dec. 1 In The United States - TradingView
The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
Is DexCom Inc. (DC4) stock cheap by valuation metricsQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
FDA clearances: Dexcom, GE HealthCare, Zimmer Biomet, BrainsWay - Modern Healthcare
DexCom, Inc. $DXCM Shares Acquired by Artisan Partners Limited Partnership - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
Will DexCom Inc. (DC4) stock profit from AI boomWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Can DexCom Inc. (DC4) stock sustain revenue momentumOil Prices & Long-Term Growth Stock Strategies - newser.com
Bragar Eagel & Squire, P.C. Urges Stockholders of DexCom, - GlobeNewswire
FDA clears Dexcom Smart Basal for insulin optimization - BioWorld MedTech
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - GlobeNewswire
Why DexCom Inc. stock is in analyst buy zoneJuly 2025 Recap & Capital Efficient Trade Techniques - newser.com
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support - Medical Economics
FDA OKs Dexcom’s Insulin Dosing Optimizer for Type 2 Diabetes - Medical Product Outsourcing
DexCom Receives US FDA Approval for Insulin Dosing Optimizer - MarketScreener
Will DexCom Inc. (DC4) stock keep high P E multiplesQuarterly Portfolio Report & Real-Time Market Sentiment Reports - newser.com
DexCom (DXCM) Gains FDA Approval for Smart Basal Insulin Dosing Optimizer - GuruFocus
Dexcom Smart Basal Receives FDA Clearance Becoming the First and - GuruFocus
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer By Investing.com - Investing.com South Africa
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes - MassDevice
Dexcom smart basal receives FDA clearance becoming the first and only CGM-integrated basal insulin dosing optimizer for type 2 diabetes - MarketScreener
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer - Investing.com Australia
2.57%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):